Asia Pacific Cell and Gene Therapy CDMO Market Size, Share By Service Area (Cell Therapy, Plasmid DNA, Viral Vector, and Others), By Indication (Cancer, Cardiovascular Disease, Infectious Disease, Genetic Disorders, Neurological Disorders), By Phase (Phase 1, Phase 2, Phase 3, Phase 4) and By Country - Trends, Analysis and Forecast till 2034

Asia Pacific Cell and Gene Therapy CDMO Market was valued at USD 1.0 billion in 2024 and is  expected to reach USD 11.3 Billion by 2034 growing at a CAGR of 29.20%

The Asia Pacific region is emerging as a dynamic hub for innovation and growth in the field of cell and gene therapy, with the Contract Development and Manufacturing Organization (CDMO) sector playing a pivotal role in advancing this transformative area of healthcare. Characterized by a rapidly expanding healthcare infrastructure, a growing biotechnology ecosystem, and increasing investment in research and development, the Asia Pacific CDMO market for cell and gene therapy is poised for significant expansion. Against the backdrop of the rising prevalence of genetic and rare diseases, coupled with the region's large and diverse patient population, there is a growing demand for advanced therapeutic solutions. CDMOs in the Asia Pacific region are uniquely positioned to meet this demand by offering specialized expertise, state-of-the-art manufacturing capabilities, and strategic geographical advantages. As a result, the Asia Pacific CDMO market represents a compelling opportunity for stakeholders across the biopharmaceutical industry to collaborate, innovate, and drive forward the development and commercialization of life-changing cell and gene therapies in this dynamic and rapidly evolving region.

Key Drivers of Target Market:

The Role of Rare Diseases

The Asia Pacific region is witnessing a significant rise in the prevalence of genetic and rare diseases, serving as a key driver for the growth of the Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) market. With increasing awareness of these conditions, there is a growing demand for innovative treatments capable of addressing their underlying genetic causes. Cell and gene therapies offer promising avenues for intervention by targeting and correcting genetic abnormalities at their source, potentially providing long-term or curative benefits for patients. As a result, biopharmaceutical companies in the Asia Pacific region are increasingly turning to CDMOs for their specialized expertise in developing and manufacturing these advanced therapies. CDMOs play a crucial role in advancing the development and commercialization of cell and gene therapies, offering end-to-end services including process development, manufacturing, and quality assurance, thereby facilitating the efficient and effective delivery of these life-changing treatments to patients in need.

Technological Advancements

Continuous technological advancements are driving the growth of the Asia Pacific Cell and Gene Therapy CDMO market. These innovations play a pivotal role in enhancing the development, manufacturing, and commercialization processes of cell and gene therapies, making them more efficient, scalable, and cost-effective. Advanced technologies such as automation, high-throughput screening, gene editing tools (e.g., CRISPR-Cas9), and viral vector production systems have revolutionized various aspects of cell and gene therapy development, allowing for faster and more precise manufacturing processes. The integration of cutting-edge technologies empowers CDMOs in the Asia Pacific region to meet the growing demand for cell and gene therapies, drive innovation in the field, and ultimately accelerate the delivery of transformative treatments to patients across the region.

Restrains:

Lack of Skilled Workforce

Despite the promising growth prospects, the Asia Pacific Cell and Gene Therapy CDMO market faces a significant challenge posed by the lack of a skilled workforce. The specialized nature of cell and gene therapy manufacturing requires highly trained personnel with expertise in cell biology, molecular biology, bioprocessing, and other relevant fields. However, there is a scarcity of professionals with the necessary skill sets and experience to effectively navigate the complex manufacturing processes and regulatory requirements associated with these advanced therapies. This shortage of skilled workforce may impede the ability of CDMOs in the Asia Pacific region to scale operations, meet project timelines, and maintain consistent product quality. Addressing this workforce challenge through targeted training programs, collaboration with academic institutions, and talent development initiatives is crucial for overcoming this restraining factor and unlocking the full potential of the Asia Pacific Cell and Gene Therapy CDMO market.

The market is segmented based on Service Area, Indication, Phase, and Country.

Asia Pacific Cell and Gene Therapy CDMO Market Report Scope:

Segments Covered in the Report:

This report forecasts revenue growth at regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2023 to 2034. For the purpose of this study segmented the Asia Pacific Cell and Gene Therapy CDMO Market report based on Service Area, Indication, Phases and Country:

Segmentation:

By Service Area:

• Cell Therapy

• Plasmid DNA
• Viral Vector
• Others    

By Indication:

• Cancer
• Cardiovascular Disease
• Infectious Disease
• Genetic Disorders
• Neurological Disorders

By Phases:

• Phase 1
• Phase 2
• Phase 3
• Phase 4

By Country:

• India
• Japan
• South Korea
• China
• Rest of Asia Pacific

The key players operating the Asia Pacific Cell and Gene Therapy CDMO Market includes Catalent Inc., LONZA GROUP, RECIPHARM AB, Wuxi Advanced Therapies, Pfizer CentreOne, Charles River Laboratories International Inc., PATHEON INC., Almac Group, and FUJIFILM DIOSYNTH BIOTECHNOLOGIES, PCI Pharma Services

• Catalent Inc., Inc. 
• LONZA GROUP
• RECIPHARM AB
• Wuxi Advanced Therapies
• Pfizer CentreOne
• Charles River Laboratories International Inc.
• PATHEON INC., INC.
• Almac Group
• FUJIFILM DIOSYNTH BIOTECHNOLOGIES
• PCI Pharma Services